ABSTRACT Several aromatic compounds have been found to inhibit the gelling of sickle cell hemoglobin. We have tried to correlate the antigelling activity of such compounds with the stereochemistry of their binding sites in the hemoglobin molecule. This approach led to the discovery that two known antilipoproteinemia drugs, clofibrate and gemfibrozil, have antigelling activity. X-ray analysis showed that three pairs of molecules of clofibric acid, the active metabolite of clofibrate, bound to the walls of the internal cavity of deoxyhemoglobin A; only one pair bound to a quite different site, between helices A, E, and H of the a chains of carbon monoxide hemoglobin A. Unlike other antigelling agents, clofibric acid and related compounds decrease rather than increase the oxygen affinity of hemoglobin.
Many chemical compounds have been studied as possible inhibitors of the gelation of sickle cell deoxyhemoglobin (Hb S), but no agent has proved sufficiently effective and innocuous to be approved for therapeutic treatment (for review, see ref. 1 ). We wondered whether x-ray diffraction studies of the binding modes of antigelling compounds to hemoglobin crystals might help us to improve their design. By what appeared to be logical arguments, we found that two known drugs-clofibric acid (CFA) and gemfibrozil (GFZ), used for treatment of patients with hyperlipoproteinemia-have antigelling activity.
The rationale for our study was as follows. Many known antigelling agents, such as phenylalanine, contain aromatic rings (2) (3) (4) (5) . Because toluene, a simple aromatic hydrocarbon, is required for the crystallization ofhuman carbon monoxide hemoglobin A (HbCO) (6) , and four to nine molecules are bound by HbCO (7, 8) , we argued that the toluene-binding sites might be related to the phenyl-binding sites of antigelling agents to Hb S. Because toluene is not observed in the HbCO electron density map (9) , two heavy atom analogues, methylphenylmercury (MePhHg) and iodobenzene, were used to try to locate the toluene site; to our surprise, MePhHg bound to two buried cysteines, making it more suitable as a heavy atom reagent for protein crystallography than as a marker for the aromatic binding site. However, C6H5I binds to HbCO near Trp-14a(A12), between helices A and E, not far from a known intermolecular contact in Hb S fibers (10) and at the binding site to deoxyhemoglobin A (Hb) of dichloromethane, which is both an anesthetic and an antisickling agent (11) . C6H51 also has weak antigelling activity. t However, a low-resolution crystal structure of Hb crystals grown in the presence of C6H5I showed no evidence of binding. X-ray analysis of crystals with antigelling aromatic amino acids gave a blank for phenylalanine with Hb and L-lysyl-L-tyrosine-HOAc with HbCO, and a multitude of small structural changes for both phenylalanine with HbCO and L-arginyl-L-tyrosine HOAc (Arg-Tyr) with Unlike other classes ofantigelling agents that raise the oxygen affinity, CFA lowers it. It also makes Hb S less soluble in concentrated ammonium sulfate or sodium potassium phosphate and more heat labile. Binding studies of CFA showed up to 10 mol (HbCO) or 12 mol (Hb) of drug per tetramer at high concentrations of drug.
MATERIALS AND METHODS CFA from Sigma was used directly, and another batch from Aldrich was recrystallized from water. GFZ was isolated from capsules made by Parke, Davis and given to us by C. Seymour. The solid material was boiled in water, filtered, and dissolved in chloroform. Removal of the solvent gave pure GFZ with the reported melting point. Arg-Tyr from Vega Biochemicals (Tucson, AZ) was given to us by A. N. Schechter.
Hb crystals were grown as described (6) Antigelling effects were measured as described (13), except that the EPR tubes were opened after centrifugation, the supernatant was removed, and Hb was assayed spectrophotometrically as the cyanide-Hb complex at 540 nm. The tubes contained Hb concentrations of 24-26 gm/100 ml. Phenylalanine also was tested for-comparison with the other compounds reported here and at 40 mM, with each run as a second control. The control solubility of Hb S (i.e., no additive) averaged 17.0 gm/100 ml for the CFA, GFZ, and phenylalanine assays (10 runs). Oxygen equilibrium curves were determined in 250-ml tonometers by using 15 ,M heme in 0.05 M [bis(2-hydroxyethyl)amino]tris(hydroxymethyl)methane, pH 7.4/0.1 M NaCl (14) . Hb was prepared by the same procedure as that used for crystallizations (6) . The binding of CFA to HbCO and Hb was determined spectrophotometrically by a modified version of the method reported for 2,3-bisphosphoglycerate (15) .
The stability of hemoglobin solutions with CFA was tested by using the methods described in ref. 16 . In the heat stability test, 150 ,uM (tetramer) solutions of HbO2 and HbO2 S in 0.15 M phosphate (pH 7.4), containing 0, 5, 10, 20, and 50 mM drug were heated for 1 hr at 500C. In the other test, the concentration of Hb and drug were the same, but-the medium was 15.3% isopropanol/0. 1 M Tris HCI, pH 7.4. The. solutions were heated to 37°C for 10 min.
X-ray diffraction data were collected on a Nonius CAD4 4-circle diffractometer for Friedel pairs to a resolution of up to 2.6 A. Crystals used ranged from 0.5 to 1.0 mm in their longest dimension. For each derivative, data from various crystals were merged; corrections for radiation damage, absorption, Lorentz and polarization factors were applied; and symmetry equivalent observations were averaged to form a unique set of intensities. Table 1 shows maximum resolution-and statistics for each derivative.
Difference electron density maps were calculated by using the refined coordinates of native Hb (17) and HbCO (9) , with Hb-p-BrBzlOAcOH coefficients IFdI -1Fj and phases ac, where Fd and Fn are observed structure amplitudes for derivative and native crystals and a6 is the phase calculated from the atomic model. For Hb derivatives, the maps were averaged over the two crystallographically independent a43 dimers if the initial map showed evidence of symmetry about the molecular dyad. The observed data for native HbCO had been collected by photographic methods (9) .
RESULTS AND DISCUSSION Fig. 1 shows. the results of our antigelling assays with CFA, GFZ, and phenylalanine and some more potent halogenated benzyloxy and phenoxy acid derivatives reported recently (18) . At 5 mM, GFZ and phenylalanine were about equivalent and more active than CFA. p-Bromobenzyloxyacetic acid and 3,4-dichlorobenzyloxyacetic acid were much -better antigelling agents at this low concentration and at 10, 20, and 40 mM. The trend in relative activity for CFA and GFZ altered slightly.at 10 mM, with CFA about equal to phenylalanine and GFZ somewhat more active. At both 20 and 40 mM, CFA was more potent than both GFZ and phenylalanine.
Because clofibrate (ethyl ester ofCFA) and GFZ are clinically approved agents for treatment of hyperlipoproteinemia, it is of interest to compare our antigelling ratios with those reported as necessary for a clinically less severe condition of sickle cell anemia. Sunshine et aL (19) have suggested that, in the double heterozygous conditions of S/,B+-thalassemia, ratios of solubil- CFA decreased the oxygen affinity of Hb at concentrations as low as 10 mM (Fig. 2) . At 40 mM and above, the oxygen affinity shifted to a value (log P = 0.98, where P50 is the oxygen pressure at which hemoglobin is half saturated) comparable to that produced by 2 mM 2,3-bisphosphoglycerate (log P50 = 1.12) at the same strength, pH, and temperature (22 Difference electron density maps of HbCO with C6H5I and i less severe, such as p-BrBzIOH' showed similar difference peaks in the cleft beglobin, solubility ratween helices A and E, near the site-occupied by Trp-14a(A12). clofibrate is recomWhen models of the compounds were fitted to the peaks, it producing a plasma became apparent that there was not enough room in the cleft entration of Hb S in for them and the indole side chain of Trp-14a(A12). The peaks iich gives a ratio of 1 can be explained only if these compounds displaced the indole ling experiments avring (Fig. 3 ). There was a positive peak, which was much sary for CFA to show stronger in the p-BrBzlOH derivative than in the C6H5I derivduce a clinical effect, ative, corresponding to a new position occupied by the indole CFA was only 1.01. ring in both maps. All'contacts between C6H5I or p-BrBzlOH and the protein were nonpolar, except for a hydrogen bond from the hydroxyl of p-BrBzlOH to the main chain carbonyl of Ala21a(B2). This residue, together with Trp-14a(A12), was close to His-20a(BI), which makes a hydrogen bond with Glu-22P(B4) of a neighboring molecule along a single fiber of Hb S (23). Therefore, distortion in this region may affect the stability of the fiber. However, because no binding has yet been established in this region for the Hb structures, we cannot offer this as a mechanism ofaction. Other peaks in both maps showed similar widespread small changes in the protein, some ofwhich appeared also in the HbCO-phenylalanine map, even though it showed no peaks in the site occupied by p-BrBzlOH or C6H51.
The difference map for CFA with HbCO also showed electron density in the site near Trp-14a(A12), hut it was not readily interpretable. Changes indicated elsewhere differed from those for C6H51 and p-BrBzlOH and were more widespread. Fig. 4 shows a projection of the electron density of Hb with CFA around the 2-fold symmetry axis running between the a subunits. The map shows four distinct regions of positive difference density related in pairs. To each of these a molecule of CFA can be fitted. Clusters ofpositive and negative difference density in several regions of the a subunits showed movements of helix F and of the C terminus of helix H to be associated with CFA binding. There were no peaks, however, near Trp-14a(A12), nor were there features in the HbCO-CFA maps in the sites observed for CFAI or CFA2 in Hb-CFA.
The electron density difference map for p-bromobenzyloxyacetic acid with Hb showed only one major peak, indicating binding at yet another site inside the CD corner of one a subunit. The noncrystallographic symmetry-related a subunit showed no binding in this region.
CONCLUSIONS
There can be a variety of approaches to the problem of preventing sickle cell formation. One consists in making derivatives FIG. 5 . Stereo diagram of the four CFA molecules bound to Hb in the same orientation as in Fig. 4 that shift the allosteric equilibrium towards the more soluble oxy form. Another, performed here, is to modify the deoxy form in some way that decreases the stability of the Hb S polymer. The initial results of this work, from the HbCO structures, seemed to encourage the design of antigelling agents on the basis of our x-ray results. The binding of the antigelling compounds C6H51, p-BrBzIOH, and, apparently, CFA to the same region in HbCO as the antigelling agent dichloromethane binds to in Hb presented a coherent picture. The finding that Hb does not bind CFA molecules there but in, the cleft between the a subunits raises doubts about the relevance of the binding site in the relaxed R structure (HbCO) to the antisickling activity. Alternatively, the linear aggregation of Hb that is common to crystallization and gelation may prevent drug binding at this position. Yet, on the other hand, dichloromethane does bind to the site near Trp-14a(A12) in the tight T structure (Hb). Even more puzzling are our observations (i) that phenylalanine and Arg-Tyr, which both have antigelling activity; have little effect on the x-ray diffraction pattern of Hb and (ii) that phenylalanine has a strong effect on the pattern. for HbCO without-showing any specific binding site; whereas.one would-expect antigelling compounds to bind to Hb rather than HbCO (i. e., the T rather than the R structure) and to bind at a specific site. At present, our intention to proceed by stereochemical logic has been thwarted by the unpredictability ofnature, but we have opened up some avenues to the development of potential antisickling agents. The results of the x-ray studies, on the other hand, are consistent with the oxygen equilibrium measurements; for they support the binding of less than two molecules of CFA to HbCO and up to six molecules of CFA to Hb.
